China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries. The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement, IMPACT Therapeutics will receive an upfront payment, near-term regulatory milestone payments, and additional commercial milestones tied to meeting specified sales targets. Senaparib is a poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor developed by IMPACT Therapeutics. Pharmanovia brings established expertise and infrastructure to the collaboration, which IMPACT Therapeutics states will assist in making the treatment more widely accessible across the covered regions.